Great post on Covid treatments from a physician on another board:
Rockleo Member Level Wednesday, 03/17/21 07:44:35 AM
Re: None 0
Post #
153236
of 153572
TURNING A NELSONS EYE TO COVID..!!!
Covid 19 infection should be considered in 2 Phases..
1. The Viral Phase-Including Asymptomatic patients to those with Mild to Moderate Symptoms-95% of infections.
2. The Hyperimmune Phase-Severe to Critical patients-5% of infections.
Our efforts to contain the Pandemic have so far been have been concentrated on what I deem the Viral Phase..
A) Antivirals like Remdesivir.
B) Monoclonal Antibody infusions against the Spike Proteins of The Virus..Bamlanivimab from Eli Lilly..Casirivimab and Imdevimab from Regeneron.
C) Convalescent Plasma utilizing antibodies against The Virus.
D) Vaccines to induce antibodies to fight The Virus.
The ‘Hope’ behind therapeutics like Remdesivir/ Convalescent Plasma/ Monoclonal Antibody infusions has faded ..As will the ‘Prayer behind Vaccines..with the Advent of Mutants emerging from Brazil..South Africa..The UK..!!!
The Case for CCR5 Inhibition being the Answer to the Covid-19 Pandemic..!!!
Geneticists trace the CCR5 Delta32 mutation to over 2500 years ago. 1% of Northern European descendants have this mutation and are resistant to both HIV and COVID.
This contrasts to the almost non existence of this mutation in Africans, East Asians and American Indians.
A) Critical Covid patients are characterized by an over expression of CCL2 and CCL4.. Two Chemokines inducing a massive influx of immune cells to the target tissues causing tremendous damage..
CCL2 and CCL4 need to be attached to a CCR1.. CCR2 or CCR5 receptor on a Macrophage to initiate the cycle of destruction..
A Monocycle in a blood vessel en route to transforming into a Macrophage in tissue..Loses it’s CCR2 Receptor. This leaves us the CCR1 and CCR5 Receptor to concentrate on..
Chua RL, et al.
B) In Critical patients a Genetic Susceptibility Locus has been identified on Chromosome 3p21.31. This cluster of 6 Genes May explain the decreased susceptibility of Blood Group O and Rhesus Negative (-) patients to Severe Covid. The CCR5 Gene is located right here..
N Engl J Med 2020..
C) Individuals with the CCR5 -Delta 32 Mutation have a significantly lower risk of Covid than controls..(p=0.002)
Furthermore individuals with this mutation are less likely to advance to the Severe Category than Controls..(p=0.036).. Gomez J. et al.
This is borne out by our CD10 Study on Mild to Moderate Covid patients.. Leronlimab treated patients showed a 96.3% improvement on Day 14 when they started with a Total Symptom Score >4.. Leronlimab treated patients required Hospitalization in 1.79% of cases while 10.71% were Hospitalized on Standard of Care..This fact could have a tremendous impact on the utilization of our Medical Resources and Economy..
Interestingly not one deletion-homozygote (Essentially CCR5 receptor absent) was found in Covid patients compared to 1% in controls.. This fact is again borne out by HIV patients on Leronlimab not having contacted Covid..to the best of our knowledge..!!!
D) Leronlimab is essentially a fully humanized Monoclonal Antibody directed against the CCR5 Receptor..It works by inhibiting the Chemokines from stimulating the Immune Cells in an uncontrolled manner..It restores the immune homeostasis in the body.. This is evidenced by a statistically significant reduction of IL-6.. Normalization of the CD4/ CD8 ratio and resolution of SARS-CoV2 Plasma viremia in the Cytokine Storm..
Patterson BK,Seethamraju H,et al.
The World Health Organization is conducting the largest randomized control trial on Covid..!!
The Solidarity Therapeutics Trial has deemed Remdesivir..Hydroxychloroquine..Lopinavir/ Ritonavir..interferon to have little or no effect on 28 day Mortality or in-hospital course of Covid-19 amoung hospitalized patients..Please evaluate our CD12 results..It is the first Phase2b/3 blinded placebo controlled trial on Severe to Critical Covid patients that shows a favorable Survival benefit..It shows in addition a statistically significant (p=0.0552) benefit in comparison to Dexamethasone..(The only therapeutic to show Mortality benefit in Covid)..Add to this the shortened time to recovery by 5.5 Days (p=0.005)..
We would request the WHO to allow Leronlimab participation in the Solidarity Trial. The World could then evaluate the efficacy of Leronlimab against the best it has to offer the Pandemic.!!!
